RecruitingISRCTN93724387

Effect of methylphenidate formulation on attention deficit hyperactivity disorder (ADHD)-patients' adherence to medical treatment. A comparison of Medikinet retard® (extended-release [ER]) once daily and Medikinet® (immediate-release [IR]) twice daily in children and adolescents diagnosed with ADHD

This recruiting study focuses on adhd and currently lists sites or participation links in Germany.

ADHDOtherFrom 6 Years to 17 Years

In plain English

Key information made simple

This study is looking at whether Before the clinical intervention, patients are observed for 4 weeks (baseline) can help people with Children and adolescents diagnosed with attention deficit hyperactivity disorder, Mental and Behavioural Disorders, or Hyperkinetic disorders. Participants take part in Before the clinical intervention, patients are observed for 4 weeks (baseline) and complete follow-up assessments. Taking part may give some people access to Before the clinical intervention, patients are observed for 4 weeks (baseline), but direct benefit is not guaranteed.

What to expect

Your next step

The official record does not clearly describe the visit format, so the practical details are best checked directly in the source. Participation appears to involve study activities and follow-up chosen by the research team. The main fit and exclusions are best confirmed in the eligibility section of the official record. The phase details are not clearly stated here.

Official source

Registry reference

This page links back to the public source record so people can verify details directly with the registry and research team.

If you want the full study description, eligibility criteria, locations, and sponsor information in the original format, this is the place to check before taking the next step.

Open source record

Need help deciding?

Ask HopeStage to review this study with me

This form records your interest so HopeStage can follow up with practical guidance. It is not a medical eligibility decision and it does not guarantee a study spot.

Study reference: ISRCTN93724387. We only ask for your email here. HopeStage can help you review the study, but this is not a medical eligibility decision.

In practice

For you

Taking part may help improve understanding of your condition.

It requires regular follow-up, often through questionnaires or interviews.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com